Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Gridelli, C., Manegold, C., Mali, P., Reck, M., Portalone, L., Castelnau, O., Stahel, R., Betticher, D., Pless, M., Pons, J.T., Aubert, D., Burillon, J.P., Parlier, Y. and De Marinis, F. (2004) Oral Vinorelbine Given as Monotherapy to Advanced, Elderly NSCLC Patients: A Multicentre Phase II Trial. European Journal of Cancer, 40, 2424-2431.
https://doi.org/10.1016/j.ejca.2004.07.028

has been cited by the following article:

  • TITLE: Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type

    AUTHORS: Amen Hamdy Zaky, Ahmed Refaat Abd Elzaher, Ola Nabih

    KEYWORDS: Lung Cancer, Maintenance Chemotherapy, Vinorelbine, EGFR-Wild Type

    JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.12, December 10, 2019

    ABSTRACT: Background: This study was performed to evaluate the efficacy and safety of switch maintenance therapy with oral vinorelbine in advanced non-small cell lung cancer (NSCLC) with adenocarcinoma limited to epidermal growth factor receptor (EGFR) wild type. Materials and Methods: In this single randomized trial, patients with advanced stage (IIIB and IV) NSCLC with adenocarcinoma EGFR wild-type status, treated with 6 cycles of platinum based chemotherapy. Patients did not show progression after first-line chemotherapy were randomly assigned to receive switch maintenance with vinorelbine (80 mg/m2, day 1, 8) (group I) or the best supportive care until disease progression (group II). Results: The median progression free survival (PFS) was 9.7 months for group I versus 5.7 months for group II with statistically significant difference between both groups [HR = 1.15; 95% CI 1.19 to 1.49; P value = 0.002], while the median overall survival (OS) was 13.2 months for group I versus 11.9 months for group II with no statistically significant differences between both groups [HR = 1.24; 95% CI 1.05 to 1.46; P value = 0. 3]. The patients who received oral vinorelbine had tolerable toxicity profile. Conclusion: Switch maintenance therapy with oral vinorelbine, though improve PFS, did not improve OS in patients with NSCLC with adenocarcinoma EGFR wild type.